Stroke

The Lancet

Volumn 389, Issue 10069, 2017, Pages 641-654

  Hankey, Graeme J ^a,b,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c Western Australian Biomedical Research Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANDEXANET ALFA; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BOTULINUM TOXIN A; CEREBROLYSIN; CIRAPARANTAG; CLOPIDOGREL; DABIGATRAN; FINGOLIMOD; FRESH FROZEN PLASMA; HEPARIN; HEPARINOID; IDARUCIZUMAB; MINOCYCLINE; PIOGLITAZONE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SEROTONIN UPTAKE INHIBITOR; TENECTEPLASE; TERUTROBAN; TICAGRELOR; TRIFLUSAL; UNINDEXED DRUG; URIC ACID; VORAPAXAR; WARFARIN;

ATRIAL FIBRILLATION; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIORESPIRATORY FITNESS; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR SURGERY; COGNITIVE REHABILITATION; CRANIECTOMY; ENDARTERECTOMY; EPIDEMIOLOGICAL DATA; HORMONAL THERAPY; MINIMALLY INVASIVE SURGERY; NEUROPROTECTION; NEUROREHABILITATION; PERCUTANEOUS THROMBECTOMY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; STEM CELL TRANSPLANTATION; TISSUE REGENERATION; TRANSIENT ISCHEMIC ATTACK; CLASSIFICATION; HUMAN; RISK FACTOR; SECONDARY PREVENTION; STROKE;

HUMANS; PROGNOSIS; RISK FACTORS; SECONDARY PREVENTION; STROKE;

EID: 84994820160     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30962-X     Document Type: Review

References (142)

1. 1 Feigin, VL, Forouzanfar, MH, Krishnamurthi, R for the Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010), the GBD Stroke Experts Group. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 383 (2014), 245–254.
2. 2 Krishnamurthi, RV, Feigin, VL, Forouzanfar, MH, et al. for the Global Burden of Diseases, Injuries Risk Factors Study 2010 (GBD 2010), for the GBD Stroke Experts Group. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health 1 (2013), e259–e281.
3. 3 Sacco, RL, Kasner, SE, Broderick, JP, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44 (2013), 2064–2089.
4. 4 Hankey, GJ, Blacker, DJ, Is it a stroke?. BMJ, 350, 2015, h56.
5. 5 Whiteley, WN, Wardlaw, JM, Dennis, MS, Sandercock, PA, Clinical scores for the identification of stroke and transient ischaemic attack in the emergency department: a cross-sectional study. J Neurol Neurosurg Psychiatry 82 (2011), 1006–1010.
6. 6 Brunser, AM, Hoppe, A, Illanes, S, et al. Accuracy of diffusion-weighted imaging in the diagnosis of stroke in patients with suspected cerebral infarct. Stroke 44 (2013), 1169–1171.
7. 7 Brazzelli, M, Chappell, FM, Miranda, H, et al. Diffusion-weighted imaging and diagnosis of transient ischemic attack. Ann Neurol 75 (2014), 67–76.
8. 8 Gibson, LM, Whiteley, W, The differential diagnosis of suspected stroke: a systematic review. J R Coll Physicians Edinb 43 (2013), 114–148.
9. 9 Bamford, J, Sandercock, P, Dennis, M, Burn, J, Warlow, C, Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337 (1991), 1521–1526.
10. 10 Adams, HP Jr, Bendixen, BH, Kappelle, LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24 (1993), 35–41.
11. 11 Amarenco, P, Bogousslavsky, J, Caplan, LR, Donnan, GA, Wolf, ME, Hennerici, MG, The ASCOD phenotyping of ischemic stroke (Updated ASCO Phenotyping). Cerebrovasc Dis 36 (2013), 1–5.
12. 12 Ay, H, Benner, T, Arsava, EM, et al. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. Stroke 38 (2007), 2979–2984.
13. 13 Hart, RG, Diener, HC, Coutts, SB, et al., the Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 13 (2014), 429–438.
14. 14 Rannikmäe, L, Woodfield, R, Anderson, CS, et al. Reliability of intracerebral haemorrhage classification systems: a systematic review. Int J Stroke 11 (2016), 626–636.
15. 15 Xie, X, Atkins, E, Lv, J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387 (2016), 435–443.
16. 16 Collins, R, Reith, C, Emberson, J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet, 2016 published online Sept 8. http://dx.doi.org/10.1016/S0140-6736(16)31357-5.
17. 17 Raman, G, Moorthy, D, Hadar, N, et al. Management strategies for asymptomatic carotid stenosis: a systematic review and meta-analysis. Ann Intern Med 158 (2013), 676–685.
18. 18 Hart, RG, Pearce, LA, Aguilar, MI, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007), 857–867.
19. 19 Mons, U, Müezzinler, A, Gellert, C, et al., for the CHANCES Consortium. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ, 350, 2015, h1551.
20. 20 Zhang, C, Qin, YY, Chen, Q, et al. Alcohol intake and risk of stroke: a dose response meta-analysis of prospective studies. Int J Cardiol 174 (2014), 669–677.
21. 21 Kernan, WN, Viscoli, CM, Furie, KL, et al., for the IRIS Trial Investigators. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med 374 (2016), 1321–1331.
22. 22 Peters, SA, Huxley, RR, Woodward, M, Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775 385 individuals and 12 539 strokes. Lancet 383 (2014), 1973–1980.
23. 23 O'Donnell, MJ, Chin, SL, Rangarajan, S, et al., for the INTERSTROKE investigators. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 388 (2016), 761–775.
24. 24 Feigin, VL, Roth, GA, Naghavi, M for the Global Burden of Diseases, Injuries and Risk Factors Study 2013, Stroke Experts Writing Group. Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol 15 (2016), 913–924.
25. 25 NINDS Stroke Genetics Network (SiGN), International Stroke Genetics Consortium. Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study. Lancet Neurol 15 (2016), 174–184.
26. 26 Neurology Working Group of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, Stroke Genetics Network (SiGN), International Stroke Genetics Consortium (ISGC). Identification of additional risk loci for stroke and small vessel disease: a meta-analysis of genome-wide association studies. Lancet Neurol 15 (2016), 695–707.
27. 27 Guiraud, V, Amor, MB, Mas, JL, Touze, E, Triggers of ischemic stroke: A systematic review. Stroke 41 (2010), 2669–2677.
28. 28 Luengo-Fernandez, R, Paul, NL, Gray, AM, et al., for the Oxford Vascular Study. Population-based study of disability and institutionalization after transient ischemic attack and stroke: 10-year results of the Oxford Vascular Study. Stroke 44 (2013), 2854–2861.
29. 29 Poon, MT, Fonville, AF, Al-Shahi Salman, R, Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 85 (2014), 660–667.
30. 30 Ayis, SA, Coker, B, Rudd, AG, Dennis, MS, Wolfe, CD, Predicting independent survival after stroke: a European study for the development and validation of standardised stroke scales and prediction models of outcome. J Neurol Neurosurg Psychiatry 84 (2013), 288–296.
31. 31 Coull, AJ, Lovett, JK, Rothwell, PM, for the Oxford Vascular Study. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ, 328, 2004, 326.
32. 32 Kiyohara, T, Kamouchi, M, Kumai, Y, et al., for the Fukuoka Stroke Registry Investigators. ABCD3 and ABCD3-I scores are superior to ABCD2 score in the prediction of short- and long-term risks of stroke after transient ischemic attack. Stroke 45 (2014), 418–425.
33. 33 Arsava, EM, Kim, G-M, Oiverira-Filho, J, et al. Prediction of Early Recurrence after Acute Ischemic Stroke. JAMA Neurol 73 (2016), 396–401.
34. 34 Wardlaw, JM, Brazzelli, M, Chappell, FM, et al. ABCD2 score and secondary stroke prevention: meta-analysis and effect per 1000 patients triaged. Neurology 85 (2015), 373–380.
35. 35 Rothwell, PM, Giles, MF, Chandratheva, A, et al., for the Early use of Existing Preventive Strategies for Stroke (EXPRESS) study. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 370 (2007), 1432–1442.
36. 36 Amarenco, P, Lavallée, PC, Labreuche, J, et al., for the TIAregistry.org Investigators. One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke. N Engl J Med 374 (2016), 1533–1542.
37. 37 Mohan, KM, Wolfe, CD, Rudd, AG, et al. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke 42 (2011), 1489–1494.
38. 38 Hijazi, Z, Lindbäck, J, Alexander, JH, et al., for the ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J 37 (2016), 1582–1590.
39. 39 Biffi, A, Anderson, CD, Battey, TW, et al. Association between blood pressure control and risk of recurrent intracerebral hemorrhage. JAMA 314 (2015), 904–912.
40. 40 Emberson, J, Lees, KR, Lyden, P, et al., for the Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 384 (2014), 1929–1935.
41. 41 Badhiwala, JH, Nassiri, F, Alhazzani, W, et al. Endovascular thrombectomy for acute ischemic stroke: a meta-analysis. JAMA 314 (2015), 1832–1843.
42. 42 Goyal, M, Menon, BK, van Zwam, WH, et al., for the HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 387 (2016), 1723–1731.
43. 43 Sandercock, PA, Counsell, C, Tseng, MC, Cecconi, E, Oral antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev, 3, 2014 CD000029.
44. 44 Yang, MH, Lin, HY, Fu, J, Roodrajeetsing, G, Shi, SL, Xiao, SW, Decompressive hemicraniectomy in patients with malignant middle cerebral artery infarction: A systematic review and meta-analysis. Surgeon 13 (2015), 230–240.
45. 45 Tsivgoulis, G, Katsanos, AH, Butcher, KS, et al. Intensive blood pressure reduction in acute intracerebral hemorrhage: a meta-analysis. Neurology 83 (2014), 1523–1529.
46. 46 Qureshi, AI, Palesch, YY, Barsan, WG, et al., the ATACH-2 Trial Investigators and the Neurological Emergency Treatment Trials Network. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med, 2016 June 8 DOI:10.1056/NEJMoa1603460.
47. 47 Mendelow, AD, Gregson, BA, Rowan, EN, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet 382 (2013), 397–408.
48. 48 Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev, 9, 2013 CD000197.
49. 49 Strbian, D, Michel, P, Seiffge, DJ, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: comparison of prediction scores. Stroke 45 (2014), 752–758.
50. 50 Anderson, CS, Robinson, T, Lindley, RI, et al., for the ENCHANTED Investigators and Coordinators. Low-Dose versus standard-dose intravenous alteplase in acute ischemic stroke. N Engl J Med 374 (2016), 2313–2323.
51. 51 Schellinger, PD, Alexandrov, AV, Barreto, AD, for the CLOTBUSTER Investigators. Combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator for emergent revascularization in acute ischemic stroke (CLOTBUST-ER): design and methodology of a multinational phase 3 trial. Int J Stroke 10 (2015), 1141–1148.
52. 52 Lyden, PD, Hemmen, TM, Grotta, J, Rapp, K, Raman, R, Endovascular therapeutic hypothermia for acute ischemic stroke: ICTuS 2/3 protocol. Int J Stroke 9 (2014), 117–125.
53. 53 Albers, GW, von Kummer, R, Truelsen, T, et al., for the DIAS-3 Investigators. Safety and efficacy of desmoteplase given 3–9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol 14 (2015), 575–584.
54. 54 Huang, X, MacIsaac, R, Thompson, JL, et al. Tenecteplase versus alteplase in stroke thrombolysis: an individual patient data meta-analysis of randomized controlled trials. Int J Stroke 11 (2016), 534–543.
55. 55 Zinkstok, SM, Roos, YB, for the ARTIS investigators. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet 380 (2012), 731–737.
56. 56 Warach, SJ, Luby, M, Albers, GW, et al., for the Stroke Imaging Research (STIR) and VISTA-Imaging Investigators. Acute stroke imaging research roadmap III imaging selection and outcomes in acute stroke reperfusion clinical trials: consensus recommendations and further research priorities. Stroke 47 (2016), 1389–1398.
57. 57 Goyal, M, Yu, AY, Menon, BK, et al. Endovascular therapy in acute ischemic stroke: challenges and transition from trials to bedside. Stroke 47 (2016), 548–553.
58. 58 Yuan, ZH, Jiang, JK, Huang, WD, Pan, J, Zhu, JY, Wang, JZ, A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia. J Clin Neurosci 17 (2010), 685–693.
59. 59 Baharoglu, MI, Cordonnier, C, Salman, RA, the PATCH Investigators. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 387 (2016), 2605–2613.
60. 60 Kuramatsu, JB, Gerner, ST, Schellinger, PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 313 (2015), 824–836.
61. 61 Steiner, T, Poli, S, Griebe, M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol 15 (2016), 566–573.
62. 62 Pollack, CV Jr, Reilly, PA, Eikelboom, J, et al. Idarucizumab for dabigatran reversal. N Engl J Med 373 (2015), 511–520.
63. 63 Siegal, DM, Curnutte, JT, Connolly, SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373 (2015), 2413–2424.
64. 64 Ansell, JE, Bakhru, SH, Laulicht, BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 371 (2014), 2141–2142.
65. 65 Aronis, KN, Hylek, EM, Who, when, and how to reverse non-vitamin K oral anticoagulants. J Thromb Thrombolysis 41 (2016), 253–272.
66. 66 Gregson, BA, Broderick, JP, Auer, LM, et al. Individual patient data subgroup meta-analysis of surgery for spontaneous supratentorial intracerebral hemorrhage. Stroke 43 (2012), 1496–1504.
67. 67 Mould, WA, Carhuapoma, JR, Muschelli, J, et al. Minimally invasive surgery plus recombinant tissue-type plasminogen activator for intracerebral hemorrhage evacuation decreases perihematomal edema. Stroke 44 (2013), 627–634.
68. 68 Ziai, WC, Tuhrim, S, Lane, K, for the CLEAR III Investigators. A multicenter, randomized, double-blinded, placebo-controlled phase III study of Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage (CLEAR III). Int J Stroke 9 (2014), 536–542.
69. 69 Bray, BD, Ayis, S, Campbell, J, et al. Associations between the organisation of stroke services, process of care, and mortality in England: prospective cohort study. BMJ, 346, 2013, f2827.
70. 70 Langhorne, P, de Villiers, L, Pandian, JD, Applicability of stroke-unit care to low-income and middle-income countries. Lancet Neurol 11 (2012), 341–348.
71. 71 Visvanathan, A, Dennis, M, Whiteley, W, Parenteral fluid regimens for improving functional outcome in people with acute stroke. Cochrane Database Syst Rev, 9, 2015 CD011138.
72. 72 Cohen, DL, Roffe, C, Beavan, J, et al. Post-stroke dysphagia: a review and design considerations for future trials. Int J Stroke 11 (2016), 399–411.
73. 73 Chamorro, Á, Dirnagl, U, Urra, X, Planas, AM, Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurol 15 (2016), 869–881.
74. 74 Bath, PM, Krishnan, K, Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database Syst Rev, 10, 2014 CD000039.
75. 75 Bath, PM, Woodhouse, L, Scutt, P, et al., for the ENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. Lancet 385 (2015), 617–628.
76. 76 Bellolio, MF, Gilmore, RM, Ganti, L, Insulin for glycaemic control in acute ischaemic stroke. Cochrane Database Syst Rev, 1, 2014 CD005346.
77. 77 Westendorp, WF, Vermeij, JD, Zock, E, et al., for the PASS investigators. The Preventive Antibiotics in Stroke Study (PASS): a pragmatic randomised open-label masked endpoint clinical trial. Lancet 385 (2015), 1519–1526.
78. 78 Kalra, L, Irshad, S, Hodsoll, J, et al., for the STROKE-INF Investigators. Prophylactic antibiotics after acute stroke for reducing pneumonia in patients with dysphagia (STROKE-INF): a prospective, cluster-randomised, open-label, masked endpoint, controlled clinical trial. Lancet 386 (2015), 1835–1844.
79. 79 CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration. Effect of intermittent pneumatic compression on disability, living circumstances, quality of life, and hospital costs after stroke: secondary analyses from CLOTS 3, a randomised trial. Lancet Neurol 13 (2014), 1186–1192.
80. 80 Geeganage, CM, Sprigg, N, Bath, MW, Bath, PMW, Balance of symptomatic pulmonary embolism and symptomatic intracerebral hemorrhage with low-dose anticoagulation in recent ischemic stroke: a systematic review and meta-analysis of randomized controlled trials. J Stroke Cerebrovasc Dis 22 (2013), 1018–1027.
81. 81 Rothwell, PM, Algra, A, Chen, Z, Diener, H-C, Norrving, B, Mehta, Z, Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 388 (2016), 365–375.
82. 82 Johnston, SC, Amarenco, P, Albers, GW, et al., for the SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 375 (2016), 35–43.
83. 83 Wong, KS, Wang, Y, Leng, X, et al. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. Circulation 128 (2013), 1656–1666.
84. 84 Rerkasem, K, Rothwell, PM, Carotid endarterectomy for symptomatic carotid stenosis. Cochrane Database Syst Rev, 4, 2011 CD001081.
85. 85 Bonati, LH, Lyrer, P, Ederle, J, Featherstone, R, Brown, MM, Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis. Cochrane Database of Syst Rev, 9, 2012 CD000515.
86. 86 Bonati, LH, Dobson, J, Featherstone, RL, et al., for the International Carotid Stenting Study investigators. Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial. Lancet 385 (2015), 529–538.
87. 87 Brott, TG, Howard, G, Roubin, GS, et al. Long-term results of stenting versus endarterectomy for carotid-artery stenosis. N Engl J Med 374 (2016), 1021–1031.
88. 88 Baigent, C, Blackwell, L, Collins, R, et al., for the Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009), 1849–1860.
89. 89 Sudlow, CL, Mason, G, Maurice, JB, Wedderburn, CJ, Hankey, GJ, Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev, 4, 2009 CD001246.
90. 90 Halkes, PH, Gray, LJ, Bath, PM, et al. Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. J Neurol Neurosurg Psychiatry 79 (2008), 1218–1223.
91. 91 Sacco, RL, Diener, HC, Yusuf, S, for the PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 359 (2008), 1238–1251.
92. 92 Kamal, AK, Naqvi, I, Husain, MR, Khealani, BA, Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev, 1, 2011 CD008076.
93. 93 Liu, L, Wang, Z, Gong, L, et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res 32 (2009), 1032–1040.
94. 94 Amarenco, P, Labreuche, J, Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 8 (2009), 453–463.
95. 95 Saxena, R, Koudstaal, PJ, Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev, 2, 2004 CD000185.
96. 96 Ruff, CT, Giugliano, RP, Braunwald, E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383 (2014), 955–962.
97. 97 Holmes, DR Jr, Doshi, SK, Kar, S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 65 (2015), 2614–2623.
98. 98 Kent, DM, Dahabreh, JH, Ruthazer, R, et al. Device closure of patent foramen ovale after stroke: Pooled analysis from all completed randomized trials. J Am Coll Cardiol 67 (2016), 907–917.
99. 99 Wang, Y, Zhao, X, Lin, J, et al., for the CHANCE investigators. Loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA 316 (2016), 70–78.
100. 100 Lee, M, Saver, JL, Hong, KS, Rao, NM, Wu, YL, Ovbiagele, B, Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. Ann Intern Med 159 (2013), 463–470.
101. 101 Sandercock, PA, Counsell, C, Kane, EJ, Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev, 3, 2015 CD000024.
102. 102 Whiteley, WN, Adams, HP Jr, Bath, PM, et al. Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials. Lancet Neurol 12 (2013), 539–545.
103. 103 Markus, HS, Hayter, E, Levi, C, Feldman, A, Venables, G, Norris, J, for the CADISS trial investigators. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. Lancet Neurol 14 (2015), 361–367.
104. 104 Rothwell, PM, Mehta, Z, Howard, SC, et al. From subgroups to individuals: general principles and the example of carotid endarterectomy. Lancet 365 (2005), 256–265.
105. 105 De Rango, P, Brown, MM, Chaturvedi, S, et al. Summary of evidence on early carotid intervention for recently symptomatic stenosis based on meta-analysis of current risks. Stroke 46 (2015), 3423–3436.
106. 106 Derdeyn, CP, Chimowitz, MI, Lynn, MJ, et al., the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet 383 (2014), 333–341.
107. 107 Zaidat, OO, Fitzsimmons, BF, Woodward, BK, et al., for the VISSIT Trial Investigators. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA 313 (2015), 1240–1248.
108. 108 Compter, A, van der Worp, HB, Schonewille, WJ, et al., for the VAST investigators. Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis: a randomised open-label phase 2 trial. Lancet Neurol 14 (2015), 606–614.
109. 109 Esposito, G, Amin-Hanjani, S, Regli, L, Role of and indications for bypass surgery after Carotid Occlusion Surgery Study (COSS)?. Stroke 47 (2016), 282–290.
110. 110 Odden, MC, McClure, LA, Sawaya, BP, et al. Achieved Blood Pressure and Outcomes in the Secondary Prevention of Small Subcortical Strokes Trial. Hypertension 67 (2016), 63–69.
111. 111 Webb, AJ, Rothwell, PM, Effect of dose and combination of antihypertensives on interindividual blood pressure variability: a systematic review. Stroke 42 (2011), 2860–2865.
112. 112 Seidu, S, Achana, FA, Gray, LJ, Davies, MJ, Khunti, K, Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials. Diabet Med 33 (2016), 280–289.
113. 113 Tuccori, M, Filion, KB, Yin, H, Yu, OH, Platt, RW, Azoulay, L, Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ, 352, 2016, i1541.
114. 114 Martí-Carvajal, AJ, Solà, I, Lathyris, D, Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev, 1, 2015 CD006612.
115. 115 Boardman, HM, Hartley, L, Eisinga, A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev, 3, 2015 CD002229.
116. 116 Lennon, O, Galvin, R, Smith, K, Doody, C, Blake, C, Lifestyle interventions for secondary disease prevention in stroke and transient ischaemic attack: a systematic review. Eur J Prev Cardiol 21 (2014), 1026–1039.
117. 117 Lawrence, M, Pringle, J, Kerr, S, Booth, J, Govan, L, Roberts, NJ, Multimodal secondary prevention behavioral interventions for TIA and stroke: a systematic review and meta-analysis. PLoS One, 10, 2015, e0120902.
118. 118 Eikelboom, JW, Connolly, SJ, Brueckmann, M, for the RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369 (2013), 1206–1214.
119. 119 Paciaroni, M, Agnelli, G, Falocci, N, et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF Study. Stroke 46 (2015), 2175–2182.
120. 120 Hijazi, Z, Oldgren, J, Lindbäck, J, et al., for the ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 387 (2016), 2302–2311.
121. 121 Kent, DM, Dahabreh, IJ, Ruthazer, R, et al. Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis. Eur Heart J 36 (2015), 2381–2389.
122. 122 Hebert, D, Lindsay, MP, McIntyre, A, et al. Canadian stroke best practice recommendations: Stroke rehabilitation practice guidelines, update 2015. Int J Stroke 11 (2016), 459–484.
123. 123 Pollock, A, Baer, G, Campbell, P, et al. Physical rehabilitation approaches for the recovery of function and mobility following stroke. Cochrane Database Syst Rev, 4, 2014 CD001920.
124. 124 Bernhardt, J, Langhorne, P, Lindley, RI, et al., for the AVERT Trial Collaboration group. Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial. Lancet 386 (2015), 46–55.
125. 125 Pollock, A, Farmer, SE, Brady, MC, et al. Interventions for improving upper limb function after stroke. Cochrane Database Syst Rev, 11, 2014 CD010820.
126. 126 Winstein, CJ, Wolf, SL, Dromerick, AW, Effect of a task-orientated rehabilitation program on upper extremity recovery following motor stroke. The ICARE randomised clinical trial. JAMA 315 (2016), 571–581.
127. 127 Mehrholz, J, Pohl, M, Platz, T, Kugler, J, Elsner, B, Electromechanical and robot-assisted arm training for improving activities of daily living, arm function, and arm muscle strength after stroke. Cochrane Database Syst Rev, 11, 2015 CD006876.
128. 128 Saunders, DH, Sanderson, M, Brazzelli, M, Greig, CA, Mead, GE, Physical fitness training for stroke patients. Cochrane Database Syst Rev, 10, 2013 CD003316.
129. 129 Mehrholz, J, Pohl, M, Elsner, B, Treadmill training and body weight support for walking after stroke. Cochrane Database Syst Rev, 1, 2014 CD002840.
130. 130 Bradt, J, Magee, WL, Dileo, C, Wheeler, BL, McGilloway, E, Music therapy for acquired brain injury. Cochrane Database Syst Rev, 7, 2010 CD006787.
131. 131 Gracies, JM, Brashear, A, Jech, R, et al., for the International AbobotulinumtoxinA Adult Upper Limb Spasticity Study Group. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. Lancet Neurol 14 (2015), 992–1001.
132. 132 Stein, C, Fritsch, CG, Robinson, C, Sbruzzi, G, Plentz, RD, Effects of Electrical Stimulation in Spastic Muscles After Stroke: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Stroke 46 (2015), 2197–2205.
133. 133 Brady, MC, Kelly, H, Godwin, J, Enderby, P, Campbell, P, Speech and language therapy for aphasia following stroke. Cochrane Database Syst Rev, 6, 2016 CD000425.
134. 134 Elsner, B, Kugler, J, Pohl, M, Mehrholz, J, Transcranial direct current stimulation (tDCS) for improving aphasia in patients with aphasia after stroke. Cochrane Database Syst Rev, 5, 2015 CD009760.
135. 135 Loetscher, T, Lincoln, NB, Cognitive rehabilitation for attention deficits following stroke. Cochrane Database Syst Rev, 5, 2013 CD002842.
136. 136 Chung, CS, Pollock, A, Campbell, T, Durward, BR, Hagen, S, Cognitive rehabilitation for executive dysfunction in adults with stroke or other adult non-progressive acquired brain damage. Cochrane Database Syst Rev, 4, 2013 CD008391.
137. 137 Bowen, A, Hazelton, C, Pollock, A, Lincoln, NB, Cognitive rehabilitation for spatial neglect following stroke. Cochrane Database Syst Rev, 7, 2013 CD003586.
138. 138 Wu, S, Kutlubaev, MA, Chun, HY, et al. Interventions for post-stroke fatigue. Cochrane Database Syst Rev, 7, 2015 CD007030.
139. 139 Mead, GE, Hsieh, CF, Lee, R, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev, 11, 2012 CD009286.
140. 140 Prasad, K, Sharma, A, Garg, A, et al., for the InveST Study Group. Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial. Stroke 45 (2014), 3618–3624.
141. 141 Kalladka, D, Sinden, J, Pollock, K, et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. Lancet 388 (2016), 787–796.
142. 142 Fearon, P, Langhorne, P, for the Early Supported Discharge Trialists. Services for reducing duration of hospital care for acute stroke patients. Cochrane Database Syst Rev, 9, 2012 CD000443.